Background: Recombinant FVIIa (rFVIIa/NovoSeven) is a novel hemostatic agent originally developed to treat patients with hemophilia who had developed inhibitors. Several case reports have suggested that rFVIIa may be effective in treating patients without a pre-existing bleeding disorder who have uncontrolled bleeding.
Study Design And Methods: Data on the efficacy and safety of rFVIIa in the treatment of massive hemorrhage were obtained retrospectively from the NovoSeven extended-use data collection system.
Results: A total of 40 patients received rFVIIa for uncontrolled bleeding, and in these patients, bleeding stopped or decreased in 32 (80%). Blood product usage was significantly decreased after rFVIIa administration. Thromboembolic events occurred in three patients with additional risk factors for thrombosis. Of 40 patients, 23 (57.5%) died. Bleeding was the direct cause of death in seven cases (all within 24 hr of administration of rFVIIa). The remaining 16 deaths were the result of sepsis, multi-organ failure, or the underlying disease.
Conclusions: In this retrospective study of data voluntarily submitted to a web-based drug surveillance program, we present preliminary results on the use of rFVIIa in nonhemophilia patients with bleeding. Although some efficacy is suggested, there was a high mortality rate from nonhemorrhagic causes. Randomized controlled trials are needed to properly assess the role of rFVIIa in the management of hemorrhage.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.0041-1132.2003.00577.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of the effect of initial hemostasis resuscitation with recombinant human coagulation factor VII a on the treatment of postoperative hemorrhage in cardiac surgery.
J Cardiothorac Surg
January 2025
Cardiac Surgery Critical Care Center Inpatient Ward 1, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Objective: To investigate the effectiveness of initial hemostatic resuscitation(IHR) on the treatment of bleeding with recombinant human coagulation factor VIIa after cardiac surgery.
Methods: The clinical data of patients who received rFVIIa hemostatic treatment after cardiac surgery at Beijing Anzhen Hospital, Capital Medical University, from January 1, 2021, to December 31, 2021 were retrospectively collected. A total of 152 cases were included in the study.
Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors.
Haemophilia
December 2024
Children's Hospital Los Angeles, Los Angeles, California, USA.
Introduction: Eptacog beta is a novel human recombinant FVIIa approved for use in the United States, European Union, United Kingdom and Mexico for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors (≥12 years). It is also indicated for perioperative care in the same patient population in Europe and the United Kingdom.
Aim: To assess the incidence of rebleeding and review treatment outcomes in subjects with haemophilia with inhibitors enrolled in the phase 3 PERSEPT 1 clinical trial.
Saliva of persons with hemophilia A triggers coagulation via extrinsic tenase complexes.
Blood
December 2024
Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Article Synopsis
- Human saliva contains extracellular vesicles (EVs) that can activate blood coagulation through the presence of extrinsic tenase complexes, which include tissue factor and activated factor VII.
- Individuals with severe hemophilia A, who lack FVIII, have salivary EVs that can compensate for their condition by generating FXa, leading to infrequent oropharyngeal bleeding.
- In contrast, people with severe FVII deficiency lack these functional extrinsic tenase complexes in their saliva, resulting in more frequent oropharyngeal bleedings; however, adding recombinant FVIIa can restore coagulation potential in their saliva.
Article Synopsis
- - Infusion of von Willebrand factor (VWF) and factor VIII (FVIII) can lead to the development of anti-VWF antibodies, complicating management of bleeding in patients with type 3 von Willebrand disease.
- - A systematic review identified 15 cases where patient management varied, with treatments including continuous FVIII infusion, recombinant FVIIa, and other strategies.
- - Emicizumab, a bispecific monoclonal antibody, was used off-label in three cases and proved effective in managing a complex local case, highlighting its potential as a treatment option for patients with allo-immunisation.
Clinical, Laboratory, and Molecular Aspects of Factor VII Deficiency.
Semin Thromb Hemost
August 2024
Independent Scientist, London, United Kingdom.
Article Synopsis
- Factor VII deficiency is a blood condition that can cause various symptoms, from minor bleeding to serious issues like bleeding in the brain.
- The effectiveness of treatments like recombinant FVIIa is being improved with new methods that last longer and offer better care for patients.
- Researchers have studied many patients and found different changes in genes that affect FVII levels, helping us understand how this condition works better over the years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!